Philips has announced the launch of its new IntraSight interventional applications platform. According to a press release, the secure, application-based platform offers a comprehensive suite of clinically proven instant wave free ratio (iFR), fractional flow reserve (FFR), intravascular ultrasound (IVUS) and co-registration modalities to simplify complex interventions and speed routine procedures.
In image-guided treatments of the heart and peripheral blood vessels, there is an increasing trend to use advanced catheters and pressure wires that are capable of producing ultrasound images of the interior of blood vessels (IVUS) and perform blood pressure measurements (FFR and iFR). There is a growing body of clinical evidence that the use of such technologies in conjunction with interventional X-ray improves patient outcomes.
“IntraSight has made an immediate impact in our lab,” says Rasha Al-Lamee, a clinical academic interventional cardiology consultant at Imperial College Healthcare NHS Trust, London, UK. “It is so simple and intuitive to use that it took us no time at all to get used to it. It has made using physiology and imaging even quicker and easier, which is a great advance for us and for our patients.”
Philips IntraSight optimises lab performance with tableside touchscreen control, systems integration, data management and remote service diagnostics. The combination of IntraSight and Azurion, Philips’ image-guided therapy platform, provides an unmatched level of diagnostic insight and intuitive tableside control that enables clinicians to provide cardiac and peripheral vascular patients with superior care. IntraSight delivers an outstanding user experience with a modern, intuitive interface that minimises learning curves and increases workflow confidence.
A significant advance in Philips’ portfolio of systems, smart devices, software and services in image-guided therapy, the scalable IntraSight platform is based on Philips’ common software and hardware architecture.
Further providing seamless integration in the interventional lab, Philips SyncVision, available on IntraSight, advances patient care by mapping both the pressure profile and IVUS measurements of the whole vessel onto the angiogram. With iFR pullback and co-registration and IVUS co-registration, physicians can identify the precise locations causing ischaemia, plan stent length and placement with a virtual stent, and predict physiologic improvement.
iFR is an innovative pressure-derived index proprietary to Philips, allowing a simplified hyperaemia-free physiological assessment of coronary blockages. It continues to be adopted into clinical practice, states a Philips’ press release, with mounting evidence that this technology contributes to reducing costs, improving outcomes and enhancing the patient experience.
IntraSight will be showcased at the Society for Cardiovascular Angiography and Interventions (SCAI) 2019 scientific sessions (19–22 May, Las Vegas, USA) and EuroPCR (21–24 May, Paris, France).
